Crystal Redman, DO
Family Medicine · Roseville, MNNPI 1740600253
Payments from drug & device makers
Across 159 payments — averaging $13.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$290
- Novo Nordisk$264
- Dexcom, Inc.$254
- AbbVie$200
- Pfizer$139
- Lilly USA, LLC$128
- plus $823 from 25 others
What the payments were for
- Food & beverage$2,098100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 19 | $290 |
| Novo Nordisk | 31 | $264 |
| Dexcom, Inc. | 19 | $254 |
| AbbVie(2 entities) | 14 | $200 |
| Pfizer | 12 | $139 |
| Lilly USA, LLC | 8 | $128 |
| AstraZeneca | 9 | $127 |
| Supernus Pharmaceuticals, Inc. | 8 | $117 |
| E.r. Squibb & Sons, L.L.C. | 4 | $65 |
| Merck | 4 | $63 |
| Bayer | 3 | $47 |
| Kowa Pharmaceuticals America, Inc. | 3 | $46 |
| Teva Pharmaceuticals USA, Inc. | 3 | $36 |
| Abbott | 2 | $33 |
| Mylan Specialty L.p. | 2 | $24 |
| Sanofi-aventis U.S. LLC | 2 | $23 |
| Novartis | 2 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Gilead | 1 | $19 |
| Shire North American Group Inc | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Alkermes, Inc. | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Grifols USA, LLC | 1 | $14 |
| Exact Sciences | 1 | $14 |
| Melinta Therapeutics, LLC | 1 | $13 |
| Ironshore Pharmaceuticals Inc. | 1 | $13 |
| Johnson & Johnson | 1 | $12 |
| GSK | 1 | $12 |
| Corium, LLC | 1 | $12 |
How this compares
$2,098 in reported general payments places this provider in the 90th percentile of 1,162 family medicine providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 31 | $61,675 |
| TrulicityDulaglutide | 29 | $39,785 |
| Tresiba Flextouch U-200Insulin Degludec | 28 | $31,666 |
| XareltoRivaroxaban | 26 | $19,269 |
| EliquisApixaban | 25 | $16,230 |
| JardianceEmpagliflozin | 15 | $13,704 |
| LinzessLinaclotide | 17 | $10,098 |
| Aimovig AutoinjectorErenumab-Aooe | 14 | $9,587 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $7,794 |
| VascepaIcosapent Ethyl | 11 | $7,178 |
| Advair HfaFluticasone Propion/Salmeterol | 20 | $7,106 |
| Spiriva HandihalerTiotropium Bromide | 12 | $6,042 |
| Dexlansoprazole DrDexlansoprazole | 15 | $4,427 |
| Doxepin Hcl | 63 | $4,151 |
| Pregabalin | 95 | $3,670 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $264 | $61,67531 claims |
| Lilly USA, LLCTrulicity | $128 | $39,78529 claims |
| Johnson & JohnsonXarelto | $12 | $19,26926 claims |
| PfizerEliquis | $139 | $16,23025 claims |
| AbbVieLinzess | $200 | $10,09817 claims |
| GSKTrelegy Ellipta | $12 | $7,79413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,162 family medicine providers in Minnesota.
Other family medicine in Roseville
- Jeffrey PetersonAda$3.6M
- Melissa ChoiSt Louis Park$825K
- John BensonMankato$498K
- Amanda LovoldSt Cloud$387K
- Robert MarshMinnetonka$300K
- Jolene BergEdina$250K
- Allan LuistroMoorhead$225K
- Mathew StaymanEast Grand Forks$220K
- Pamela NollMinneapolis$178K
- Taylor MertzMoorhead$176K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.